These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

795 related items for PubMed ID: 21047883

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M.
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [Abstract] [Full Text] [Related]

  • 24. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, Ciesielczyk B, Neubert K, Wiltfang J, Kretzschmar HA, Poser S, Otto M.
    J Neural Transm (Vienna); 2005 Jul; 112(7):933-48. PubMed ID: 15937638
    [Abstract] [Full Text] [Related]

  • 25. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
    Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D, Zetterberg H, Padovani A, Bonanni L, Mollenhauer B, Schade S, Vandenberghe R, Poesen K, Kramberger MG, Paquet C, Bousiges O, Cretin B, Willemse EAJ, Teunissen CE, Lemstra AW, European-Dementia With Lewy Bodies (E-DLB) ConsortiumFrom the Department of Laboratory Medicine (K.B., E.R.B., E.A.J.W., C.E.T.) and Alzheimer Center Amsterdam (A.A.J.M.U., A.W.L.), Amsterdam UMC, the Netherlands; Department of Quality and Health Technology (M.C.G.), University of Stavanger; The Norwegian Centre for Movement Disorders (M.C.G.) and the Centre for Age-Related Medicine (M.C.G., N.J.A., D.A.), Stavanger University Hospital, Norway; Department of Psychiatry and Neurochemistry (N.J.A., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Old Age Psychiatry (N.J.A., D.A.), King's College London, United Kingdom; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Hong Kong, China; Wisconsin Alzheimer's Disease Research Center (H.Z.), University of Wisconsin School of Medicine and Public Health, Madison; Neurology Unit (A.P.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Medicine and Aging Sciences (L.B.), University G. d'Annunzio of Chieti-Pescara, Chieti, Italy; Department of Neurology (B.M.), University Medical Center Göttingen; Paracelsus-Elena-Klinik (B.M., S.S.), Germany; Department of Neurosciences (R.V., K.P.), KU Leuven, Belgium; Department of Neurology and Medical Faculty (M.G.K.), University Medical Center Ljubljana, Slovenia; Department of Neurobiology (M.G.K.), Karolinska Institutet, Huddinge, Sweden; Université de Paris Cité (C.P.), Centre de Neurologie Cognitive, Paris; Laboratory of Biochemistry and Molecular Biology (O.B.), University Hospital of Strasbourg; University of Strasbourg and CNRS (O.B., B.C.); Memory Resource and Research Centre (B.C.), University Hospital of Strasbourg, France; Department of Neurology (E.A.J.W.), Multiple Sclerosis Center; Research Center for Clinical Neuroimmunology and Neuroscience Basel (E.A.J.W.); and Departments of Biomedicine and Clinical Research (E.A.J.W.), University Hospital Basel and University of Basel, Switzerland..
    Neurology; 2024 Jun 25; 102(12):e209418. PubMed ID: 38830138
    [Abstract] [Full Text] [Related]

  • 26. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
    de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG.
    Aging Clin Exp Res; 2023 Aug 25; 35(8):1741-1752. PubMed ID: 37264166
    [Abstract] [Full Text] [Related]

  • 27. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Dement Geriatr Cogn Disord; 2005 Aug 25; 19(2-3):164-70. PubMed ID: 15637452
    [Abstract] [Full Text] [Related]

  • 28. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
    Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, Sikkes SA.
    J Neurol Neurosurg Psychiatry; 2017 Feb 25; 88(2):113-118. PubMed ID: 27794030
    [Abstract] [Full Text] [Related]

  • 29. Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias.
    Baiardi S, Abu-Rumeileh S, Rossi M, Zenesini C, Bartoletti-Stella A, Polischi B, Capellari S, Parchi P.
    Ann Clin Transl Neurol; 2019 Feb 25; 6(2):263-273. PubMed ID: 30847359
    [Abstract] [Full Text] [Related]

  • 30. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 25; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 31. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG.
    J Alzheimers Dis; 2021 Oct 25; 81(3):1295-1309. PubMed ID: 33935098
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.
    J Neurol Sci; 2014 Aug 15; 343(1-2):120-4. PubMed ID: 24928081
    [Abstract] [Full Text] [Related]

  • 34. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 35. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jul 22; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 36. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
    Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.
    JAMA Neurol; 2017 Dec 01; 74(12):1492-1501. PubMed ID: 29114726
    [Abstract] [Full Text] [Related]

  • 37. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA.
    Mov Disord; 2018 Nov 01; 33(11):1724-1733. PubMed ID: 30440090
    [Abstract] [Full Text] [Related]

  • 38. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, Yébenes JG, del Ser T.
    Arch Neurol; 2003 Sep 01; 60(9):1218-22. PubMed ID: 12975286
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar 01; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.